株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

次世代シーケンシング (NGS) 市場およびNGSラボの調査

Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories

発行 Kalorama Information 商品コード 910374
出版日 ページ情報 英文 186 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
次世代シーケンシング (NGS) 市場およびNGSラボの調査 Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories
出版日: 2019年08月02日 ページ情報: 英文 186 Pages
概要

当レポートでは、シーケンシング市場および次世代シーケンシング (NGS) を使用するラボについて詳細に調査し、シーケンシングシステム市場の収益推計、消耗品市場の収益推計、製品タイプ別のシェア推計と予測、およびベンダー別による地域内訳と市場シェアなどに関するデータを提供するとともに、ラボマネージャー・ディレクターへのインタビュー調査結果をまとめています。

第1章 市場分析・調査サマリー

第2章 システム導入

  • 全体的なインストールベース
  • インストールベース:地域別
  • インストールベース:産業セグメント別
  • インストールベース:ラボ機能別

第3章 シーケンサーの用途、臨床用途、および利用動向

  • シーケンサーの用途・利用
  • 臨床用途

第4章 参考資料・評価

  • シーケンサー選択の主な基準
  • 変更点または改善点
  • プロセスにおける障壁

第5章 将来の購入計画

  • 購入計画のタイムフレーム
  • 購入を検討する可能性のあるシステム

第6章 企業プロファイル

  • 10X GENOMICS
  • BGI GENOMICS (FORMERLY BEIJING GENOME INSTITUTE)
  • ILLUMINA
  • OXFORD NANOPORE
  • PROMEGA CORPORATION
  • QIAGEN N.V.
  • ROCHE DIAGNOSTICS
  • SWIFT BIOSCIENCES
  • THERMO FISHER SCIENTIFIC INC.

付録

目次
Product Code: 19-045

Next-generation sequencing (NGS) technologies encompass the modern, post-Sanger sequencing techniques that revolutionized and expanded the fields of molecular biology and genomics in recent years. NGS has been a disruptive technology that had a substantial impact on the characterization of the genome of various species and has found numerous applications in a large variety of fields, including clinical diagnostics, drug discovery and development, agriculture, and forensics. ‘Next-Generation Sequencing Market and Kalorama Survey of NGS Laboratories’ provides an in-depth look at the sequencing market, including data for 2018-2023 for the following markets:

  • NGS Sequencing Market, 2018-2023
  • Estimated Sequencing System Market Revenues, 2018-2023
  • Estimated Sequencing System Consumable Market Revenues, 2018-2023
  • Estimated Sequencing System Market Revenues, 2018-2023
  • Estimated Shares by Product Type, 2018 (%)
  • Forecast Shares by Product Type, 2023 (%)
  • Regional Breakout and Market Share by Vendor

This report includes a Survey of Labs Using Next-Generation Sequencing. The survey was conducted by an experienced NGS market analyst who interviewed lab managers and directors to obtain a real-world view point on the next-generation sequencing market today.

  • Please describe the lab's industry and function?
  • How many sequencers does the laboratory have, and which models?
  • For your most recent sequencers, please describe: the model, what applications are run typically (by percentage), how often or how many samples (runs, samples, slides, flow cells, plates, multiplexed or not).
  • Which applications are expected to increase most?
  • Does the lab outsource any sequencing? For what reason(s)?
  • How does the lab/ organization address regulated patient samples?
  • Does the lab have accreditation for regulated patient samples?
  • Which sequencers are used for regulated and non-regulated patient samples?
  • In what disease areas does the lab sequence regulated/ non-regulated patient/ human samples? What disease areas are expected to grow the most from 2017-2018?
  • What percentage of samples sequenced are patient samples subject to regulation, patient/ human samples not subject to regulation, and non-patient/ non-human samples not subject to regulation? How is this expected to change from 2017-2018
  • How much is the volume of NGS and capillary sequencing expected to change overall from 2017 to 2018?
  • What sequencer features, or steps in the sequencing process would you most like to be changed/ improved?
  • What is the main bottleneck in your sequencing process (ie at what step do things back up)?
  • How challenging are data analysis and data management?
  • Which systems would the lab most likely consider for future purchases?
  • What is the likely time-frame for future sequencer purchases?
  • Which systems are likely to be used in the future for regulated patient samples (and are not being used currently for that)?
  • What barriers or other issues would hinder the growth of sequencing, particularly NGS, in clinical areas?

Company profiles - next-generation sequencing companies:

  • 10X Genomics
  • BGI Genomics (formerly Beijing Genome Institute)
  • Illumina
  • Oxford Nanopore
  • Promega Corporation
  • Qiagen N.V.
  • Roche Diagnostics
  • Swift Biosciences
  • Thermo Fisher Scientific Inc.

Table of Contents

1: MARKET ANALYSIS AND REPORT SUMMARY

  • OVERALL SEQUENCING MARKET REVENUES
    • Table 1-1: NGS Sequencing Market, 2018-2023
    • Table 1-2: Estimated Sequencing System Market Revenues, 2018-2023
    • Table 1-3: Estimated Sequencing System Consumable Market Revenues, 2018-2023
    • Table 1-4: Estimated Sequencing System Market Revenues, 2018-2023
    • Figure 1-1: Estimated Shares by Product Type, 2018 (%)
    • Figure 1-2: Forecast Shares by Product Type, 2023 (%)
  • Regional Breakout
    • Figure 1-3: Regional Breakout
  • Market Share
    • Figure 1-4: Market Share by Vendor
  • SCOPE
  • METHODOLOGY
  • OUTLINE
  • DEMOGRAPHICS
  • Regional Distribution of Respondents' Labs
    • Table 1-5: Regional Distribution of Respondent Labs
    • Figure 1-5: Regional Distribution of Respondent Labs (%)
  • Industrial Distribution of Respondents' Labs
    • Table 1-6: Primary Industry/ Segment Labs Belong To
    • Figure 1-6: Primary Industry/ Segment Labs Belong To (%)
    • Table 1-7: Industry/ Segment(s) Labs Belong To, by Region
    • Table 1-8: Industry/ Segment(s) Labs Belong To, by Region (%)
    • Figure 1-7: Industry/ Segment(s) Labs Belong To, by Region (%)
  • Laboratory Function of Respondents' Labs
    • Table 1-9: Major Function(s) of Respondent Labs
    • Figure 1-8: Major Function(s) of Respondent Labs (%)
    • Table 1-10: Major Function(s) of Labs, by Region
    • Table 1-11: Major Function(s) of Labs, by Region (%)
    • Figure 1-9: Major Function(s) of Labs, by Region (%)
  • Distribution by Number of Sequencers
    • Table 1-12: Distribution of Total Sequencers in Labs
    • Figure 1-10: Distribution of Total Sequencers in Labs
    • Table 1-13: Number of Next-Generation Sequencers in Labs
    • Figure 1-11: Number of Next-Generation Sequencers in Labs
    • Table 1-14: Number of ABI Capillary Sequencers in Labs
    • Figure 1-12: Number of ABI Capillary Sequencers in Labs
  • Brand(s)/ Types(s) of Sequencers Owned, Overall
    • Table 1-15: Brand(s)/ Type(s) of Sequencers Owned by Labs
    • Table 1-16: Number of a Given Brand / Type in Labs Owning Type, 2019
    • Figure 1-13: Avg. Number of a Given Sequencer in Labs Owning Type, 2019
    • Table 1-17: Number of a Given Brand / Type in Labs Owning Type, 2017
    • Figure 1-14: Avg. Number of a Given Sequencer in Labs Owning Type, 2017
  • Library Preparation and Other Automation
    • Table 1-18: Library Preparation and Automation Systems
  • Position/ Role of Respondents
    • Table 1-19: Position/ Role of Respondent
    • Figure 1-15: Position/ Role of Respondent (%)

2: SYSTEM INSTALLATIONS

  • OVERALL INSTALLED BASE
  • Distribution of Sequencer Models
    • Table 2-1: Sequencer Models in Respondents' Labs
    • Figure 2-1: Sequencer Models in Respondents' Labs (%)
    • Table 2-2: Installed Base of Labs, by System(s) Owned (# of Systems)
    • Table 2-3: Installed Base of Labs, by System(s) Owned (% of Systems)
    • Figure 2-2: Installed Base of Labs, by System(s) Owned (% of Systems)
    • Table 2-4: Installed Base of Labs, by System(s) Owned (% of Systems)
  • Distribution of Number of Sequencers
    • Table 2-5: Distribution of NGS vs. Capillary Systems (# of Labs)
    • Figure 2-3: Distribution of NGS vs. Capillary Systems (# of Labs)
    • Table 2-6: # of NGS Systems by # of Capillary Systems (% of Labs)
    • Figure 2-4: # of NGS Systems by # of Capillary Systems (% of Labs)
    • Table 2-7: # of Capillary Systems by # of NGS Systems (% of Labs)
    • Figure 2-5: # of Capillary Systems by # of NGS Systems (% of Labs)
  • INSTALLED BASE BY REGION
  • Overall Brand/ Type
    • Table 2-8: Number of Systems Installed in Labs, by Region
    • Table 2-9: Sequencer Models in Respondents' Labs, by Region (# of Systems)
    • Table 2-10: Sequencer Models in Respondents' Labs, by Region (% of Systems)
    • Figure 2-6: Sequencer Models in Respondents' Labs, by Region (% of Systems)
  • Next-Generation Systems
    • Table 2-11: NGS Models in Respondents' Labs, by Region (# of Systems)
    • Table 2-12: NGS Models in Respondents' Labs, by Region (% of Systems)
    • Figure 2-7: NGS Models in Respondents' Labs, by Region (% of Systems)
  • Capillary Systems
    • Table 2-13: Capillary Models in Respondents' Labs, by Region (# of Systems)
    • Table 2-14: Capillary Models in Respondents' Labs, by Region (% of Systems)
    • Figure 2-8: Capillary Models in Respondents' Labs, by Region (% of Systems)
  • INSTALLED BASE BY INDUSTRY SEGMENT
  • Overall Brand/ Type
    • Table 2-15: Number of Systems Installed, by Industry/ Segment(s)
    • Table 2-16: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (# of Systems)
    • Table 2-17: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
    • Figure 2-9: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2017 (% of Systems)
    • Table 2-18: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
    • Figure 2-10: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2019 (% of Systems)
    • Table 2-19: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (# of Systems)
    • Table 2-20: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (% of Systems)
    • Table 2-21: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (% of Systems)
  • Next-Generation Systems
    • Table 2-22: Number of NGS Systems Installed, by Industry/ Segment
    • Table 2-23: Next-Generation Models in Respondents' Labs, by Industry/ Segment (# of Systems)
    • Table 2-24: Next-Generation Models in Respondents' Labs, by Industry/ Segment (% of Systems)
    • Figure 2-11: Next-Generation Models in Respondents' Labs, by Industry/ Segment (% of Systems)
    • Table 2-25: Next-Generation Models in Respondents' Labs, by Industry/ Segment (% of Systems)
    • Figure 2-12: Next-Generation Models in Respondents' Labs, by Industry/ Segment (% of Systems)
  • Capillary Systems
    • Table 2-26: Number of Capillary Systems Installed in Labs Owning, by Industry/ Segment
  • INSTALLED BASE BY LABORATORY FUNCTION
  • Overall Brand/ Type
    • Table 2-27: Number of Systems Installed by Laboratory Function
    • Table 2-28: Brand / Type of Sequencer System Installed, by Lab Function (# of Systems)
    • Table 2-29: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
    • Figure 2-13: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
    • Table 2-30: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
    • Figure 2-14: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems)
  • Next-Generation Systems
    • Table 2-31: Number of NGS Installed in Labs Owning, by Lab Function
    • Table 2-32: NGS Models in Respondents' Labs, by Lab Function (# of Systems)
    • Table 2-33: NGS Models in Respondents' Labs, by Lab Function (% of Systems)
    • Figure 2-15: NGS Models in Respondents' Labs, by Lab Function (% of Systems)
    • Table 2-34: NGS Models in Respondents' Labs, by Lab Function (% of Systems)
    • Figure 2-16: NGS Models in Respondents' Labs, by Lab Function (% of Systems)
  • Capillary / Gel Systems
    • Table 2-35: Number of Capillary Systems Installed in Labs Owning, by Lab Function

3: SEQUENCER APPLICATIONS, CLINICAL APPLICATIONS, AND USAGE TRENDS

  • SEQUENCER APPLICATIONS AND USAGE
  • Applications Run, Overall and by Brand/ Type
    • Table 3-1: NGS Application Volume by Model (% of Sequencing)
    • Figure 3-1: NGS Application Volume by Model (% of Sequencing)
  • Likely Increases in Applications and Volume
    • Table 3-2: Applications Expected to Increase the Most, 2019
    • Figure 3-2: Applications Expected to Increase the Most Overall (%)
    • Table 3-3: Applications Expected to Increase, by NGS Brand Owned (# of Labs)
    • Table 3-4: Applications Expected to Increase, by NGS Brand Owned (% of Labs)
    • Figure 3-3: Applications Expected to Increase, by NGS Brand Owned (% of Labs)
    • Table 3-5: Expected Growth in Sequencing Volume (# of Labs)
    • Table 3-6: Expected Growth in Sequencing Volume (% of Labs)
    • Figure 3-4: Expected Growth in Sequencing Volume (% of Labs)
  • Capacity Usage of Systems
    • Table 3-7: Avg. Percentage of Systems' Capacity Used, by Brand
    • Figure 3-5: Percentage of Systems' Capacity Used, by Brand
  • Outsourcing
    • Table 3-8: Percentage of Sequencing Volume Outsourced
    • Figure 3-6: Percentage of Sequencing Volume Outsourced
    • Table 3-9: Percentage of Sequencing Volume Outsourced, by Region
    • Table 3-10: Percentage of Sequencing Volume Outsourced, by Region
    • Table 3-11: Reasons for Outsourcing
    • Figure 3-7: Reasons for Outsourcing (%)
  • CLINICAL APPLICATIONS
  • Sequencing of CLIA Regulated Patient Samples
    • Table 3-12: How Labs Address Sequencing of Regulated Patient Samples (# of Labs)
    • Table 3-13: How Labs Address Sequencing of Regulated Patient Samples (% of Labs)
    • Figure 3-8: How Labs Address Sequencing of Regulated Patient Samples (% of Labs)
  • Certification for Regulated Samples
    • Table 3-14: Labs' Certification for Regulated Patient Samples
    • Figure 3-9: Labs' Certification for Regulated Patient Samples (%)
    • Table 3-15: Distribution of Samples, Est. 2018 (# of Labs)
    • Table 3-16: Distribution of Samples, Est. 2017 (% of Labs)
    • Figure 3-10: Distribution of Samples, Est. 2018 (% of Labs)
    • Table 3-17: Distribution of Samples, Expected 2019 (# of Labs)
    • Table 3-18: Distribution of Samples, Expected 2019 (% of Labs)
    • Figure 3-11: Distribution of Samples, Expected 2019 (% of Labs)
    • Table 3-19: Proportion of Regulated vs. Non-Regulated Samples (% of Sequencing)
    • Figure 3-12: Proportion of Regulated vs. Non-Regulated Samples, Est. 2018 (% of Sequencing)
    • Figure 3-13: Proportion of Regulated vs. Non-Regulated Samples, Expected 2019 (% of Sequencing)
    • Table 3-20: Proportion of Regulated vs. Non-Regulated Samples (% of Sequencing)
    • Figure 3-14: Proportion of Regulated vs. Non-Regulated Samples, est. 2018 (% of Sequencing)
    • Figure 3-15: Proportion of Regulated vs. Non-Regulated Samples, Expected 2014 (% of Sequencing)
  • Sequencers Used or Planned for Patient/ Human Samples
    • Table 3-21: Sequencers Used for Regulated Patient Samples
    • Figure 3-16: Sequencers Used for Regulated Patient Samples (% of Systems)
  • Disease/ Therapeutic Areas Where Sequencing Applied
    • Table 3-22: Disease Areas Where Sequencing Applied, NGS (Percentage and Number of Systems)
    • Figure 3-17: Disease Areas Where Sequencing Applied (%)
    • Table 3-23: Regulated Sequencing Expected to Grow Fastest
    • Figure 3-18: Regulated Sequencing Expected to Grow Fastest (% of Labs)
    • Table 3-24: Non-Regulated Patient/ Human Sequencing Expected to Grow Fastest
    • Figure 3-19: Non-Regulated Patient/ Human Sequencing Expected to Grow Fastest
  • Challenges for Growth of Clinical Sequencing
    • Table 3-25: Challenges for Growth of Clinical Sequencing

4: PREFERENCES AND EVALUATIONS

  • KEY CRITERIA FOR CHOOSING SEQUENCERS
  • Overall
    • Table 4-1: Most Important Criteria for Sequencer Purchase
    • Figure 4-1: Most Important Criteria for Sequencer Purchase (%)
  • By Next-Generation Systems vs Capillary Systems
    • Table 4-2: Most Important Criteria for Purchases, by Brand Owned
    • Table 4-3: Most Important Criteria for Purchase, by Brand Owned
  • CHANGES OR IMPROVEMENTS
    • Table 4-4: Feature Most Wanted to Change or Improve
    • Figure 4-2: Feature Most Wanted to Change or Improve (%)
  • BOTTLENECKS IN PROCESS
    • Table 4-5: Bottlenecks in the NGS Process
    • Figure 4-3: Bottlenecks in the NGS Process (%)

5: FUTURE PURCHASE PLANS

  • TIME-FRAME OF PURCHASE PLANS
  • Overall
    • Table 5-1: Time Frame for Future Purchase
    • Figure 5-1: Time Frame for Future Purchase (%)
  • By Brand/ Type Owned
    • Table 5-2: Time Frame for Future Purchase, by Brand Owned (# of Labs)
    • Table 5-3: Time Frame for Future Purchase, by Brand Owned (% of Labs)
  • By Laboratory Function
    • Table 5-4: Time Frame for Future Purchase, by Lab Function (# of Labs)
    • Table 5-5: Time Frame for Future Purchase, by Lab Function (% of Labs)
  • By Region
    • Table 5-6: Time Frame for Future Purchase, by Region (# of Labs)
    • Table 5-7: Time Frame for Future Purchase, by Region (% of Labs)
    • Figure 5-2: Time Frame for Future Purchase, by Region (% of Labs)
  • SYSTEMS LIKELY TO CONSIDER FOR PURCHASE
  • Overall
    • Table 5-8: Sequencer Models Likely to Consider, 2019-2020
    • Figure 5-3: Sequencer Models Likely to Consider (% of Labs)
  • By Brand/ Type Owned
    • Table 5-9: Sequencer Models Likely to Consider, by Brand/ Type Owned (# of Labs)
    • Table 5-10: Sequencer Models Likely to Consider, by Brand/ Type Owned (% of Labs)
    • Figure 5-4: Sequencer Models Likely to Consider, by Brand/ Type Owned (% of Labs)
  • By Industry/ Segment
    • Table 5-11: Sequencer Models Likely to Consider, by Industry/ Segment Owned (# of Labs)
    • Table 5-12: Sequencer Models Likely to Consider, by Industry/ Segment Owned (% of Labs)
  • By Laboratory Function
    • Table 5-13: Sequencer Models Likely to Consider, by Lab Function (# of Labs)
    • Table 5-14: Sequencer Models Likely to Consider, by Lab Function (% of Labs)
  • By Region
    • Table 5-15: Sequencer Models Likely to Consider, by Region (# of Labs)
    • Table 5-16: Sequencer Models Likely to Consider, by Region (% of Labs)
    • Figure 5-5: Sequencer Models Likely to Consider, by Region (% of Labs)

6: COMPANY PROFILES

  • 10X GENOMICS
  • BGI GENOMICS (FORMERLY BEIJING GENOME INSTITUTE)
  • ILLUMINA
    • Key Comment
    • Recent Revenue History
    • Company Reported Highlights in 2018
  • OXFORD NANOPORE
  • PROMEGA CORPORATION
  • QIAGEN N.V.
    • Key Comment
    • Recent Revenue History
    • Tuberculosis
    • Molecular Expansion
    • Precision Medicine / Companion Diagnostics
    • Liquid Biopsy
  • ROCHE DIAGNOSTICS
    • Key Comment
    • Revenues
  • SWIFT BIOSCIENCES
  • THERMO FISHER SCIENTIFIC INC.
    • Key Comment
    • Recent Revenue History
    • Next Generation Sequencing

APPENDIX: LIBRARY PREPARATION

  • Table A-1: Library Preparation Related Systems (% of Systems, Count)
  • Figure A-1: Library Preparation Related Systems (% of Systems)
  • Table A-2: Library Preparation Related Systems (% of Labs Responding, Count)
  • Figure A-2: Library Preparation Related Systems (% of Labs Responding)
Back to Top